AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2011
Jan 19, 2011
29977_dirs_2011-01-19_fd2e3e6b-86c5-40b5-8c05-25bab2a99af0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2011-01-18
Reporting Person: BROWN MICHAEL S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-01-18 | Common Stock | M | 5000 | $18.8 | Acquired | 29662 | Direct |
| 2011-01-18 | Common Stock | F | 2694 | $34.88 | Disposed | 26968 | Direct |
| 2011-01-18 | Common Stock | M | 5000 | $15.01 | Acquired | 31968 | Direct |
| 2011-01-18 | Common Stock | F | 2151 | $34.88 | Disposed | 29817 | Direct |
| 2011-01-19 | Common Stock | S | 2306 | $35.6 | Disposed | 27511 | Direct |
| 2011-01-19 | Common Stock | S | 2849 | $35.59 | Disposed | 24662 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-01-18 | Non-Qualified Stock Option (right to buy) | $15.01 | M | 5000 | Disposed | 2014-01-02 | Common Stock (5000) | Direct |
| 2011-01-18 | Non-Qualified Stock Option (right to buy) | $18.8 | M | 5000 | Disposed | 2013-01-02 | Common Stock (5000) | Direct |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: The reporting person sold 2,306 shares of Company stock on January 19, 2011 at prices ranging from $35.50 to $35.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 19, 2011 at each separate price.
F3: The reporting person sold 2,849 shares of Company stock on January 19, 2011 at prices ranging from $35.50 to $35.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 19, 2011 at each separate price.
F4: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant
F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.